
    
      This Phase 1a , single-dose trial incorporates an open-label, ascending dose strategy to
      determine the safety & tolerability of MKC253 (GLP1/TechnosphereÂ®)Inhalation Powder.

      The trial consists of a screening, dosing and a follow-up visit. Single dose administration
      of MKC253 occurs at the dosing visit. Five doses are being assessed: 0.05, 0.45, 0.75, 1.05 &
      1.5 mg GLP-1. Dosing of each ascending cohort will occur after the Principal Investigator has
      reviewed all safety/tolerability data
    
  